Arcutis Q4 2025 revenue $127.5M, first profitable quarter; 2026 guidance raised to $480-495M

Arcutis Biotherapeutics, Inc.

2025-FY EPS reported -$0.13 revenue$376,072,000

Q4 net product revenue $127.5M (+84% YoY, +29% sequential); full year $372.1M (+123% YoY).
Q4 net income $17.4M ($0.14 diluted EPS) vs net loss of $10.8M in Q4 2024; positive operating cash flow of $26.2M.
Raised 2026 net product revenue guidance to $480-495M from $455-470M.
Positive Phase 2 data for ZORYVE cream 0.05% in infants (3-24 months) with atopic dermatitis; sNDA submission expected Q2 2026.
sNDA accepted for ZORYVE cream 0.3% in plaque psoriasis down to age 2; PDUFA June 29, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.